Research

Hormonal

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce a weight loss plateau over time, suggesting that appetite suppression alone is insufficient for sustained weight management and highlighting the need for complementary thermogenic strategies.

If you are on a GLP-1 medication like semaglutide or liraglutide and your weight loss has stalled after the first year, this is a common physiological plateau, not a failure. The medication's appetite-suppressing effect has maxed out. To continue losing weight, you may need to add strategies that increase energy expenditure, such as exercise-induced thermogenesis or potentially future thermogenic medications, rather than just relying on the drug alone.

GoodQualifiesHIGH confidence
However, many patients reach a weight loss plateau over time, suggesting that appetite regulation alone may be insufficient for achieving and maintaining a desired weight loss... after the first year, weight loss tended to plateau despite continued therapy.
Sahar Soliman et al. · Pharmaceuticals · 2025

Why this rating

The paper cites specific clinical trials (e.g., 2-year liraglutide study, NEJM study) demonstrating the plateau effect.

Source

Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies

Sahar Soliman et al. · Pharmaceuticals · 2025

DOI 10.3390/ph18101519

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →